DMAC Stock Price, DiaMedica Therapeutics Quote, Chart

Market Summary

USD3.170.00

Market Closed

0.00%

DMAC Stock Price

View Fullscreen

DMAC RSI Chart

DMAC Valuation

Market Cap

120.3M

Price/Earnings (Trailing)

-6.25

Price/Sales (Trailing)

642.61

EV/EBITDA

-6.16

Price/Free Cashflow

-5.93

DMAC Price/Sales (Trailing)

DMAC Profitability

EBT Margin

-9374.15%

Return on Equity

-41.55%

Return on Assets

-39.1%

Free Cashflow Yield

-16.86%

DMAC Fundamentals

DMAC Revenue

Revenue (TTM)

205.0K

DMAC Earnings

Earnings (TTM)

-19.3M

Earnings Growth (Yr)

2.3%

Earnings Growth (Qtr)

0.19%

Breaking Down DMAC Revenue

Last 7 days

1.6%

Last 30 days

21.9%

Last 90 days

8.2%

Trailing 12 Months

50.6%

How does DMAC drawdown profile look like?

DMAC Financial Health

Current Ratio

18.14

DMAC Investor Care

Shares Dilution (1Y)

40.95%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	797.0K	636.0K	398.0K	205.0K
2019	589.0K	678.0K	767.0K	856.0K
2018	0	0	0	500.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of DiaMedica Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 02, 2024	pilnik richard d.	acquired	84,999	2.8	30,357	-
Jan 02, 2024	semba charles pauling	acquired	26,250	2.8	9,375	-
Jan 02, 2024	parsons james t.	acquired	59,998	2.8	21,428	-
Jan 02, 2024	giuffre randall michael	acquired	53,748	2.8	19,196	-
Jan 02, 2024	kuntz richard	acquired	39,998	2.8	14,285	-
Nov 16, 2023	wambeke david j.	bought	49,200	2.46	20,000	chief business officer
Jun 23, 2023	von koch thomas	bought	5,000,000	3.4	1,470,590	-
Jun 23, 2023	semba charles pauling	bought	49,997	3.91	12,787	-
Jun 23, 2023	pauls dietrich john	bought	49,997	3.91	12,787	president and ceo
Jun 23, 2023	pilnik richard d.	bought	149,999	3.91	38,363	-

Which funds bought or sold DMAC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-35.87	-25,272	42,209	-%
May 15, 2024	Royal Bank of Canada	reduced	-21.9	-1,000	2,000	-%
May 15, 2024	CITADEL ADVISORS LLC	added	5.75	2,024	66,535	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-81,920	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-62.89	-13,162	7,468	-%
May 15, 2024	Aristides Capital LLC	unchanged	-	-7,444	294,542	0.11%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	1,274	1,274	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-43.00	-	-%
May 15, 2024	FIRST MANHATTAN CO. LLC.	added	640	2,028,730	2,354,600	0.01%
May 15, 2024	MORGAN STANLEY	reduced	-24.32	-89,969	253,657	-%

Are Funds Buying or Selling DMAC?

Are funds buying DMAC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DMAC

No. of Funds

Unveiling DiaMedica Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jun 27, 2023	tomenterprise ab	0.0%	0	SC 13G/A
Jun 27, 2023	trill ab	10.6%	4,021,608	SC 13G/A
Jun 23, 2023	jacinto richard ii	12.0%	4,558,823	SC 13G/A
Feb 13, 2023	lynch timothy p	0.4%	100,259	SC 13G/A
Jan 13, 2023	jacinto richard ii	9.5%	2,500,000	SC 13G/A
Dec 06, 2022	tomeqt private ab	0.0%	0	SC 13G/A
Jul 12, 2022	tomenterprise ab	10.8%	2,855,847	SC 13G/A
May 27, 2022	jacinto richard ii	6.2%	1,649,053	SC 13G
Feb 15, 2022	lytton laurence w	4.1%	1,071,970	SC 13G/A
Feb 11, 2022	stonepine capital management, llc	4.5%	1,194,670	SC 13G/A

Recent SEC filings of DiaMedica Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K	Current Report
May 08, 2024	10-Q	Quarterly Report
Apr 10, 2024	8-K	Current Report
Apr 09, 2024	EFFECT	EFFECT
Apr 04, 2024	DEFA14A	DEFA14A
Apr 04, 2024	DEF 14A	DEF 14A
Apr 04, 2024	ARS	ARS
Apr 04, 2024	CORRESP	CORRESP
Mar 26, 2024	UPLOAD	UPLOAD
Mar 21, 2024	S-3	S-3

Peers (Alternatives to DiaMedica Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

DiaMedica Therapeutics Inc News

Latest updates

DiaMedica Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)										(In Thousands)
Description	(%) Q/Q	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-100.0%	-	25.00	65.00	115	193	263	226	174	337	500
Operating Expenses	-	-	-	-	-	-	-	-	3,421	-	-
S&GA Expenses	0.8%	1,171	1,161	1,108	1,055	968	1,044	867	814	667	777
R&D Expenses	43.5%	3,098	2,158	1,600	1,349	1,802	1,617	1,874	2,607	1,451	1,210
Income Taxes	250.0%	7.00	2.00	9.00	9.00	2.00	12.00	8.00	9.00	6.00	57.00
Earnings Before Taxes	-31.4%	-4,193	-3,191	-2,465	-2,416	-2,478	-2,436	-2,461	-3,243	-1,956	-1,330
Net Income	-31.5%	-4,200	-3,193	-2,474	-2,425	-2,480	-2,448	-2,469	-3,252	-1,962	-1,387

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.0%	49.00	54.00	58.00	62.00	30.00	34.00	37.00	39.00	42.00	46.00	49.00	22.00	24.00	28.00	31.00	13.00	14.00	9.00	11.00	13.00	15.00
Current Assets	-11.5%	47.00	54.00	48.00	41.00	30.00	34.00	36.00	39.00	42.00	45.00	49.00	22.00	24.00	28.00	31.00	12.00	14.00	9.00	11.00	12.00	15.00
Cash Equivalents	-53.8%	2.00	5.00	2.00	6.00	2.00	5.00	3.00	3.00	3.00	5.00	16.00	2.00	3.00	7.00	10.00	5.00	3.00	4.00	5.00	3.00	3.00
Net PPE	0.8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	-6.1%	3.00	3.00	2.00	2.00	3.00	2.00	2.00	2.00	1.00	2.00	2.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Shareholder's Equity	-9.2%	46.00	51.00	56.00	60.00	27.00	32.00	35.00	38.00	41.00	44.00	47.00	20.00	23.00	26.00	30.00	11.00	13.00	8.00	10.00	12.00	14.00
Retained Earnings	-4.4%	-120	-115	-110	-105	-101	-96.18	-92.40	-89.40	-86.01	-82.50	-79.25	-75.81	-72.53	-68.91	-64.71	-61.52	-59.04	-56.62	-54.14	-51.69	-49.22
Additional Paid-In Capital	0.3%	167	167	166	166	129	128	128	127	127	127	126	96.00	96.00	95.00	94.00	73.00	72.00	64.00	64.00	63.00	63.00
Shares Outstanding	0.0%	38.00	38.00	38.00	38.00	26.00	26.00	26.00	26.00	26.00	26.00	19.00	19.00	-	-	-	-	-	-	-	-	-
Float	-100.0%	-	103	-	-	-	53.00	-	-	-	-	-	78.00	-	-	-	79.00	-	-	-	53.00	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-75.8%	-6,653	-3,784	-4,797	-5,030	-5,089	-2,766	-2,361	-2,496	-3,888	-2,804	-3,046	-2,089	-4,313	-3,016	-2,347	-844	-2,978	-1,865	-1,232	-2,871	-3,134
Share Based Compensation	7.0%	488	456	425	380	422	411	418	365	308	298	303	446	511	506	508	436	393	401	451	182	130
Cashflow From Investing	-31.3%	4,208	6,124	1,196	-28,128	2,509	4,724	2,072	2,528	2,214	-8,689	-12,828	989	-9.00	667	-14,000	2,500	-5,301	1,008	3,000	3,012	-10,928
Cashflow From Financing	0%	-1.00	-1.00	-6.00	36,850	-1.00	-1.00	-2.00	-2.00	-1.00	-19.00	29,865	-1.00	242	-39.00	21,189	-1.00	7,696	-1.00	-1.00	74.00	-2.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DMAC Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 3,676	$ 3,618
General and administrative	2,065	1,903
Total operating expenses	(5,741)	(5,521)
Other income, net	597	256
Loss before income tax expense	(5,144)	(5,265)
Income tax expense	(7)	(7)
Net loss	(5,151)	(5,272)
Other comprehensive (loss) gain
Unrealized gain (loss) on marketable securities	(45)	45
Net loss and comprehensive loss	$ (5,196)	$ (5,227)
Basic and diluted net loss per share (in dollars per share)	$ (0.14)	$ (0.2)
Weighted average shares outstanding – basic and diluted (in shares)	37,958,000	26,448,941

DMAC Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,097	$ 4,543
Marketable securities	44,419	48,352
Prepaid expenses and other assets	569	411
Amounts receivable	399	369
Total current assets	47,484	53,675
Non-current assets:
Deposits	1,308	0
Operating lease right-of-use asset, net	336	354
Property and equipment, net	132	131
Total non-current assets	1,776	485
Total assets	49,260	54,160
Current liabilities:
Accounts payable	716	926
Accrued liabilities	1,815	1,777
Operating lease obligation	83	80
Finance lease obligation	3	3
Total current liabilities	2,617	2,786
Non-current liabilities:
Operating lease obligation	294	316
Finance lease obligation	0	1
Total non-current liabilities	294	317
Shareholders’ equity:
Common shares, no par value; unlimited authorized; 37,963,916 and 37,958,000 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Paid-in capital	167,097	166,609
Accumulated other comprehensive income (loss)	(39)	6
Accumulated deficit	(120,709)	(115,558)
Total shareholders’ equity	46,349	51,057
Total liabilities and shareholders’ equity	$ 49,260	$ 54,160

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CEO	Mr. Dietrich John Pauls MBA
WEBSITE	diamedica.com
INDUSTRY	Biotechnology
EMPLOYEES	16

DiaMedica Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for DiaMedica Therapeutics Inc? What does DMAC stand for in stocks?

DMAC is the stock ticker symbol of DiaMedica Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of DiaMedica Therapeutics Inc (DMAC)?

As of Fri May 17 2024, market cap of DiaMedica Therapeutics Inc is 120.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DMAC stock?

You can check DMAC's fair value in chart for subscribers.

What is the fair value of DMAC stock?

You can check DMAC's fair value in chart for subscribers. The fair value of DiaMedica Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of DiaMedica Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DMAC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is DiaMedica Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether DMAC is over valued or under valued. Whether DiaMedica Therapeutics Inc is cheap or expensive depends on the assumptions which impact DiaMedica Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DMAC.

What is DiaMedica Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, DMAC's PE ratio (Price to Earnings) is -6.25 and Price to Sales (PS) ratio is 642.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DMAC PE ratio will change depending on the future growth rate expectations of investors.